ISIS Pharma

Thanks to Jim Cramer for pointing this one out.

ISIS Pharma. They put out a press release talking about how good their new experimental drug is. They also says that the drug had a "strong safety profile".

Then they're quarterly report says the drug had some liver issues.

Shame on this company for putting out a press release intended to mislead the investing public.

Who's on this board?

Stanley T Crooke, M.D. Ph.D.
Chairman of the Board and Chief Executive Officer
Isis Pharmaceuticals, Inc.

Spencer R. Berthelsen, M.D.
Chairman and Managing Director
Kelsey-Seybold Clinic

Richard D. DiMarchi, Ph.D.
Professor and the Jack and Linda Gill Distinguished Chair, Biomolecular Science, Indiana University

Joseph Klein, III
Managing Director
Gauss Capital Advisors LLC

Frederick T. Muto, J.D.
Partner
Cooley Godward LLP

B. Lynne Parshall, J.D.
Executive Vice President, Chief Financial Officer and Secretary
Isis Pharmaceuticals, Inc.

John C. Reed, M.D., Ph.D.
President and Chief Executive Officer
The Burnham Institute

Joseph H. Wender
Senior Managing Director
GSC Partners